Author/Authors :
Kolgelier، Servet نويسنده Department of Infectious Diseases and Clinical Microbiology, Adiyaman University Faculty of Medicine, Adiyaman, Turkey , , Demir، Nazlim Aktug نويسنده Department of Infectious Diseases and Clinical Microbiology, Selcuk University Faculty of Medicine, Konya, Turkey , , Inkaya، Ahmet Cagkan نويسنده Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Hacettepe University, Ankara, Turkey , , Sumer، Sua نويسنده Department of Infectious Diseases and Clinical Microbiology, Selcuk University Faculty of Medicine, Konya, Turkey , , Ozcimen، Serap نويسنده Department of Infectious Diseases and Clinical Microbiology, Konya State Hospital, Konya, Turkey , , Demir، Lutfi Saltuk نويسنده Department of Public Health, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey , , Pehlivan، Fatma Seher نويسنده Department of Pathology, Adiyaman State Hospital, Adiyaman, Turkey , , Arslan، Mahmure نويسنده Department of Biochemistry, Adiyaman State Hospital, Adiyaman, Turkey , , Arpaci، Abdullah نويسنده Department of Biochemistry, Faculty of Medicine, Adiyaman University, Adiyaman, Turkey ,
Abstract :
Hepatologists have studied serologic markers of liver injury for decades. Annexins are a prominent group of such markers and annexin A2 (AnxA2) is one of the best characterized annexins. AnxA2 inhibits HBV polymerase among other functions. Its expression is up-regulated in regenerative hepatocytes. To determine if serum AnxA2 level has a role in estimating liver damage in chronic HBV infection and investigate whether AnxA2 levels correlate with hepatic fibrosis. This study included 173 patients with chronic hepatitis B (CHB) and 51 healthy controls. Liver fibrosis was graded histologically on liver biopsy samples. Blood samples were taken from patients during biopsy and serum AnxA2 levels were measured with ELISA. In a group of adult patients with CHB, AnxA2 values were far higher than those of the control group (P = 0.001). When we assessed AnxA2 levels based on fibrosis stages, serum AnxA2 levels of patients with early stage fibrosis (stages 1 - 3) were significantly higher than those of patients with advanced stage fibrosis (stages 4 - 5; P = 0.001). AnxA2 is a useful biomarker for early stage fibrosis in patients with CHB.
